Form 4: Vaxcyte Director Acquires Shares and Options

Vaxcyte, Inc. Director Jacks Lee acquired 2,265 shares of common stock and was granted options for 11,389 shares.

Summary

• Director Jacks Lee acquired 2,265 shares of Vaxcyte, Inc. common stock on June 15, 2026.
• Lee also received a stock option grant for 11,389 shares of common stock with an exercise price of $49.56.
• The acquired shares are related to restricted stock units (RSUs) that will vest on June 15, 2027, or the day before the next annual meeting.
• The stock options will also vest monthly and fully vest by June 15, 2027, or the day before the next annual meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents standard insider compensation and stock acquisition rather than a significant strategic shift or financial event.

Positives

• Director acquisition of company stock can signal confidence in the company's future prospects.
• Granting of stock options aligns management incentives with shareholder value creation.

Risks

• Vesting of RSUs and stock options is subject to continuous service through the vesting date, meaning departure from the company before then could result in forfeiture.
• The exercise price of the stock options ($49.56) is significantly higher than the current market price, implying a substantial increase in share price is needed for these options to become profitable.

Future Outlook

The RSUs and stock options are set to vest by June 15, 2027, or the day prior to the next annual meeting of stockholders, contingent upon the reporting person's continued service with the company.

Industry Context

StockSavvy.ai notes that insider transactions, such as this Form 4 filing by a Vaxcyte director, are closely watched by the market as potential indicators of management's view on the company's valuation and future performance, particularly within the biotechnology sector where stock-based compensation is prevalent.

Stakeholder Impact

• Shareholders: The acquisition of shares by a director may be viewed positively, suggesting insider confidence. However, the high exercise price of options indicates a need for significant stock appreciation to benefit the holder.
• Employees: The vesting schedule for RSUs and options aligns with typical employee and director compensation structures, incentivizing long-term commitment.
• Management: The stock options grant serves as a performance incentive for management.

Next Steps

• Continuous service by Jacks Lee through June 15, 2027, or the day prior to the next annual meeting, for full vesting of RSUs and stock options.

Key Dates

Keywords

Vaxcyte, PCVX, Form 4, Insider Trading, Stock Options, RSUs, Director Compensation, Beneficial Ownership